Literature DB >> 28695772

Circular RNA GLI2 promotes osteosarcoma cell proliferation, migration, and invasion by targeting miR-125b-5p.

Ji-Feng Li1, Yu-Ze Song1.   

Abstract

Circular RNAs are novel identified type of endogenous non-coding RNAs, which exert vital functions in human and animals. However, the in-depth role of circular RNAs in the progression of tumorigenesis, especially osteosarcoma, is still undefined. Our preliminary study had found that cir-GLI2 was significantly upregulated in osteosarcoma tissues compared to adjacent non-tumor tissue. Moreover, cir-GLI2 silencing could effectively suppress the proliferation, migration, and invasion capacity of osteosarcoma cells, indicating the tumor-promoting role. Besides, bioinformatics analysis and luciferase reporter assay predicted the direct binding to miR-125b-5p, which has been reported to function as a tumor suppressor in osteosarcoma. Furthermore, functional experiments validated that cir-GLI2 exerted the tumor-promoting effects on osteosarcoma cells via negatively targeting miR-125b-5p. In conclusion, our study demonstrated that cir-GLI2 acts as an oncogenic circular RNA in osteosarcoma genesis, providing a novel diagnostic and therapeutic target for osteosarcoma.

Entities:  

Keywords:  Osteosarcoma; cir-GLI2; circular RNAs; invasion; miR-125b-5p; proliferation

Mesh:

Substances:

Year:  2017        PMID: 28695772     DOI: 10.1177/1010428317709991

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  17 in total

1.  Microarray profiles reveal that circular RNA hsa_circ_0007385 functions as an oncogene in non-small cell lung cancer tumorigenesis.

Authors:  Ming-Ming Jiang; Zhi-Tao Mai; Shan-Zhi Wan; Yu-Min Chi; Xin Zhang; Bao-Hua Sun; Qing-Guo Di
Journal:  J Cancer Res Clin Oncol       Date:  2018-01-25       Impact factor: 4.553

2.  Silencing hsa_circRNA_0008035 exerted repressive function on osteosarcoma cell growth and migration by upregulating microRNA-375.

Authors:  Gu Gong; Zhifeng Han; Wenjun Wang; Qinli Xu; Jingzhe Zhang
Journal:  Cell Cycle       Date:  2020-08-11       Impact factor: 4.534

3.  Circ-PAX2 promotes proliferation and metastasis by absorbing miR-186 in lung cancer cells.

Authors:  Lei Wang; Cong Xu; Chenghai Wang; Weijuan Gong; Kefan Zhang; Qiuyue Chen; Shishi Zhou; Tingyue Qi
Journal:  Int J Clin Exp Pathol       Date:  2018-07-01

Review 4.  Circular RNAs in Sepsis: Biogenesis, Function, and Clinical Significance.

Authors:  Jesús Beltrán-García; Rebeca Osca-Verdegal; Elena Nacher-Sendra; Federico V Pallardó; José Luis García-Giménez
Journal:  Cells       Date:  2020-06-25       Impact factor: 6.600

5.  Circ-SFMBT2 promotes the proliferation of gastric cancer cells through sponging miR-182-5p to enhance CREB1 expression.

Authors:  Handong Sun; Pengcheng Xi; Zhiqiang Sun; Qian Wang; Bin Zhu; Jian Zhou; Hui Jin; Wubin Zheng; Weiwei Tang; Hongyong Cao; Xiufeng Cao
Journal:  Cancer Manag Res       Date:  2018-11-16       Impact factor: 3.989

Review 6.  Emerging important roles of circRNAs in human cancer and other diseases.

Authors:  Yong Huang; Cai Zhang; Jianli Xiong; Hongtao Ren
Journal:  Genes Dis       Date:  2020-08-07

7.  Circular RNA circ-NT5C2 acts as an oncogene in osteosarcoma proliferation and metastasis through targeting miR-448.

Authors:  Xunfa Liu; Yuanbo Zhong; Jifeng Li; Aijun Shan
Journal:  Oncotarget       Date:  2017-10-30

8.  Overexpressed circPVT1, a potential new circular RNA biomarker, contributes to doxorubicin and cisplatin resistance of osteosarcoma cells by regulating ABCB1.

Authors:  Zhu Kun-Peng; Ma Xiao-Long; Zhang Chun-Lin
Journal:  Int J Biol Sci       Date:  2018-02-12       Impact factor: 6.580

Review 9.  Emerging Roles of Circular RNAs in Osteosarcoma.

Authors:  Chenyu Wang; Ming Ren; Xin Zhao; Ao Wang; Jincheng Wang
Journal:  Med Sci Monit       Date:  2018-10-04

10.  Expression of circ_001569 is upregulated in osteosarcoma and promotes cell proliferation and cisplatin resistance by activating the Wnt/β-catenin signaling pathway.

Authors:  Hongfei Zhang; Jiapeng Yan; Xujian Lang; Yuesheng Zhuang
Journal:  Oncol Lett       Date:  2018-09-06       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.